FDA Panel Backs Orexigen's Diet Pill
After the U.S. Food and Drug Administration rejected two other weight-loss pills earlier this year, an advisory panel has recommended the approval of Orexigen Therapeutics's Contrave. If the FDA follows the recommendation, Contrave could become the first diet drug to win approval in a decade. Continue reading FDA Panel Backs Orexigen's Diet Pill FDA Panel Backs Orexigen's Diet Pill originally appeared on DailyFinance on Tue, 07 Dec 2010 20:30:00. Filed Under: Company News , Health Care , Stocks in the News Permalink | Tweet this! | Comments
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here